Arvinas (ARVN) Change in Accured Expenses (2017 - 2026)
Arvinas (ARVN) recorded quarterly Change in Accured Expenses of -$6.8 million in Q1 2026, down 142.5% quarter-over-quarter from $16.0 million in Q4 2025, and down 750.0% on a YoY basis from $1.0 million in Q1 2025.
Arvinas (ARVN) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Arvinas' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$6.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 750.0% year-over-year to -$6.8 million; the TTM figure through Mar 2026 stood at -$7.7 million (down 22.22% YoY), while the FY2025 annual figure was -$1.7 million, up 91.98% from the prior year.
- Change in Accured Expenses was -$6.8 million for Q1 2026 at Arvinas, down from $16.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $25.2 million in Q4 2022 to a low of -$16.8 million in Q2 2025.
- Historically, Change in Accured Expenses has averaged $458823.5 across 5 years, with a median of -$100000.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses surged 3750.0% in 2022, then slumped 1033.33% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $25.2 million in 2022, then sank by 94.84% to $1.3 million in 2023, then plunged by 476.92% to -$4.9 million in 2024, then soared by 426.53% to $16.0 million in 2025, then plunged by 142.5% to -$6.8 million in 2026.
- The last three Change in Accured Expenses figures came in at -$6.8 million (Q1 2026), $16.0 million (Q4 2025), and -$100000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -6.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.80 Mn |
| Mar 31, 2026 | -6.80 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Dec 31, 2025 | 16.00 Mn |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -16.80 Mn |
| Jun 30, 2025 | -16.80 Mn |
| Mar 31, 2025 | -800,000.00 |
| Mar 31, 2025 | -800,000.00 |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Mar 31, 2024 | -15.70 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Dec 31, 2023 | 1.30 Mn |